期刊
JOURNAL OF CLINICAL MEDICINE
卷 9, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/jcm9061766
关键词
HHT; ALK1; endoglin; raloxifene; bazedoxifene; tranexamic acid; propranolol; FK506; etamsylate; N-acetylcysteine
资金
- Ministry of Economy and Competitivity [SAF2017-83351-R]
The diagnosis of hereditary hemorrhagic telangiectasia (HHT) is based on the Curacao criteria: epistaxis, telangiectases, arteriovenous malformations in internal organs, and family history. Genetically speaking, more than 90% of HHT patients show mutations inENGorACVRL1/ALK1genes, both belonging to the TGF-beta/BMP9 signaling pathway. Despite clear knowledge of the symptoms and genes of the disease, we still lack a definite cure for HHT, having just palliative measures and pharmacological trials. Among the former, two strategies are: intervention at ground zero to minimize by iron and blood transfusions in order to counteract anemia. Among the later, along the last 15 years, three different strategies have been tested: (1) To favor coagulation with antifibrinolytic agents (tranexamic acid); (2) to increase transcription ofENGandALK1with specific estrogen-receptor modulators (bazedoxifene or raloxifene), antioxidants (N-acetylcysteine, resveratrol), or immunosuppressants (tacrolimus); and (3) to impair the abnormal angiogenic process with antibodies (bevacizumab) or blocking drugs like etamsylate, and propranolol. This manuscript reviews the main strategies and sums up the clinical trials developed with drugs alleviating HHT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据